Besides the strategies of neurotransmitter modulator interference and amyloid beta peptide (Aβ)-targeted plaque clearance, neuroinflammatory inhibitors have been widely explored as potential therapeutic approaches for AD, targeting toll-like receptors (TLRs), nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), NOD-, LRR- and pyrin domain-containing protein 3 (NLRP3) inflammasome, among others (2–5). The gene discussed is NFKB1; the disease is Alzheimer disease.